Alzheimer's Drugs Market will be US$ 15.08 Billion by 2032

Alzheimer’s Drugs Market Analysis

The global market for Alzheimer’s drugs reached US$ 6.9 billion in 2023 and is projected to reach US$ 15.08 billion by 2032, with an expected annual growth rate of 8.9 percent from 2024 to 2032.

Alzheimer’s disease is a debilitating condition characterized by a progressive decline in memory, cognitive function, and the ability to perform everyday tasks. Currently, there is no cure for Alzheimer’s disease, but there are medications available that can help manage its symptoms and slow its progression over time. The most commonly prescribed drugs for Alzheimer’s disease are cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine. These medications work by increasing the levels of a neurotransmitter called acetylcholine, which is reduced in the brains of individuals with Alzheimer’s. Cholinesterase inhibitors can enhance cognitive function, memory, and behavior in some individuals by boosting acetylcholine levels. According to the World Health Organization, more than fifty-five million people worldwide are living with dementia, with Alzheimer’s disease being the most prevalent form. It is projected that this number will nearly double over the next two decades, reaching 82 million by 2030 and 152 million by 2050.

Request a free sample copy of the report: https://www.renub.com/alzheimer-s-pipeline-drugs-review-alzheimer-s-disease-drug-market-and-forecast-global-analysis-131-p.php

Growth drivers of the Alzheimer’s drugs market

Aging Population: The increasing global elderly population, especially individuals aged 65 and older, is a significant driver of demand for Alzheimer’s drugs. As people age, the prevalence of Alzheimer’s disease rises sharply, necessitating effective treatments to manage symptoms and improve quality of life. This demographic shift not only expands the patient pool requiring Alzheimer’s medications but also underscores the urgent need for innovative therapies to address the growing burden of this neurodegenerative condition. Pharmaceutical companies and healthcare providers are increasingly focused on developing and delivering drugs that can effectively alleviate symptoms and potentially modify the course of Alzheimer’s disease, reflecting the critical importance of meeting the healthcare needs of an aging population.

Advancements in Research: Ongoing research into the pathophysiology of Alzheimer’s disease and the development of new therapeutic targets are pivotal in expanding treatment options and advancing pipeline development. Scientists are investigating the complex mechanisms underlying Alzheimer’s, including amyloid plaques, tau protein abnormalities, and neuroinflammation, to identify novel drug targets. These efforts aim to develop therapies that can effectively slow disease progression, preserve cognitive function, and enhance quality of life for patients. Collaborative research initiatives, supported by academia, pharmaceutical companies, and government funding, drive innovation in Alzheimer’s drug discovery. As new insights into disease mechanisms emerge, promising candidates move through preclinical and clinical trials, offering hope for breakthrough treatments that could address the significant unmet medical need in Alzheimer’s disease management.

Government Initiatives and Funding: Supportive government policies, funding initiatives, and regulatory incentives aimed at accelerating drug development for Alzheimer’s disease play a crucial role in stimulating market growth and fostering innovation. Governments worldwide recognize the increasing societal and economic burden of Alzheimer’s and are implementing policies to facilitate research and development in this area. Funding initiatives provide financial support for basic research, clinical trials, and translational studies, encouraging collaboration among researchers and pharmaceutical companies. Regulatory incentives, such as expedited review processes and extended market exclusivity, incentivize investment in Alzheimer’s drug development by reducing time-to-market and enhancing commercial viability. These supportive measures not only attract investment in novel therapies but also streamline the pathway for promising treatments to reach patients faster. Ultimately, they contribute to advancing Alzheimer’s treatments and improving outcomes for individuals affected by this devastating neurodegenerative disease.

Rising Awareness and Diagnosis: Improved awareness about Alzheimer’s disease symptoms and advancements in diagnostic techniques are pivotal in driving earlier detection and treatment initiation, thereby expanding the patient pool and increasing demand for effective drugs. Recognizing early signs such as memory loss, cognitive decline, and behavioral changes prompts individuals and healthcare providers to seek timely medical evaluation. Early diagnosis allows for interventions that may slow disease progression and improve patient outcomes. As awareness campaigns educate the public and healthcare professionals about Alzheimer’s, more cases are identified at earlier stages, increasing the number of individuals requiring therapeutic intervention. This heightened awareness also emphasizes the importance of developing and accessing effective treatments to manage symptoms and potentially modify the course of Alzheimer’s disease, addressing the growing healthcare challenge posed by an aging global population.

China Alzheimer’s Drugs Market

China is currently facing a growing challenge with its aging population, leading to a significant increase in the prevalence of neurological conditions like Alzheimer’s disease and other forms of dementia. Alzheimer’s remains the leading cause of death in China, ranking fifth among prevalent causes. This has put a substantial financial strain on individuals, families, and society at large. In China, over 15 million people aged 60 and above are living with dementia, with Alzheimer’s disease accounting for 62% of these cases. The prevalence of Alzheimer’s increases with age, affecting 2-5% of those aged 65 and above and 15-20% of those aged 80 and above. This has resulted in a significant financial burden, with billions of yuan being spent annually and putting pressure on healthcare resources. To address this, China’s ‘Healthy China Action’ strategy aims to shift the focus from disease treatment to health maintenance for the growing population affected by Alzheimer’s disease and related dementias (ADRD).

In China, healthcare reimbursement is primarily managed by the National Healthcare Security Administration (NHSA), covering over 95% of the population. Reimbursement rates vary based on insurance plans and the necessity and significance of medical treatments received. An important development in this context took place in January 2024 when Eisai and Biogen announced the approval of their Alzheimer’s medication, Leqembi, in China. This made China the third country, after the United States and Japan, to approve this medication for the treatment of Alzheimer’s disease.

Alzheimer’s Drugs Market Company Overview

Industry leaders in the Alzheimer’s drug market include Abbvie, AstraZeneca, Biogen, Eisai, Eli Lilly, Lundbeck, Roche, Merck, Novartis, Ono Pharmaceutical, Pfizer, and Teva.

Alzheimer’s Drugs Market News

Eisai’s LEQEMBI was approved in China in January 2024 to treat Alzheimer’s.
In July 2023, AbbVie Inc. expanded its collaboration with nonprofit Scripps Research’s Caliber to develop preclinical and early-stage clinical assets for the biopharmaceutical business. The cooperation intends to create disease treatments.
Leqembi obtained its regulatory clearance in July 2023. The US FDA has approved Lecanemab-irmb for the treatment of Alzheimer’s disease.

Eli Lilly & Company revealed positive results from the TRAILBLAZER-ALZ 2 Phase III research in May 2023, indicating that donanemab improved impairment in Alzheimer’s patients in the early stages.
In September 2022, Lecanemab demonstrated promising results in a Phase 3 clinical trial, indicating that it can potentially treat Alzheimer’s.
Eisai Co. Ltd. and Washington University of Medicine announced a collaboration in December 2022 to explore cures for Alzheimer’s disease and other mental diseases.
In June 2021, Biogen’s Aduhelm will become the first FDA-approved Alzheimer’s medicine in nearly two decades.
In 2021, the Alzheimer’s Association funded the AMP-AD Target Discovery and Preclinical Validation Project with $5.5 million to discover new therapeutic targets for Alzheimer’s treatment.

Drug Class – Market breakup in 4 viewpoints:

1. Cholinesterase Inhibitors

2. NMDA Receptor Antagonist

3. Combination Drugs

4. Others

Drug Type –Market breakup in 5 viewpoints:

1. Galantamine

2. Donepezil

3. Memantine

4. Rivastigmine

5. Others

Distribution Channel –Market breakup in 3 viewpoints:

1. Hospital Pharmacies

2. Retail Pharmacies

3. Online Pharmacies

Country – Market of 25 Countries Covered:

1. North America

1.1 United States

1.2 Canada

2. Europe

2.1 France

2.2 Germany

2.3 Italy

2.4 Spain

2.5 United Kingdom

2.6 Belgium

2.7 Netherlands

2.8 Turkey

3 Asia Pacific

3.1 China

3.2 Japan

3.3 India

3.4 South Korea

3.5 Thailand

3.6 Malaysia

3.7 Indonesia

3.8 Australia

3.9 New Zealand

4 Latin America

4.1 Brazil

4.2 Mexico

4.3 Argentina

5 Middle East & Africa

5.1 Saudi Arabia

5.2 UAE

5.3 South Africa

All the Key players have been covered from 4 Viewpoints:

1. Overview

2. Recent Development

3. Product Portfolio

4. Financial Insights

Company Analysis:

1. Abbvie Inc.

2. AstraZeneca PLC

3. Biogen Inc.

4. Eisai Co. Ltd.

5. Eli Lilly and Company

6. H. Lundbeck A/S

7. F. Hoffmann-La Roche AG

8. Merck & Co. Inc.

9. Novartis AG

10. Ono Pharmaceutical Co. Ltd.

11. Pfizer Inc.

12. Teva Pharmaceutical Industries Limited

Schizophrenia Drugs Market

Narcolepsy Drugs Market

About the Company:

Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.

Contact Us:

Renub Research

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Email: info@renub.com

LinkedIn: https://in.linkedin.com/company/renub-research

Website: https://www.renub.com/